Lipoprotein

CHICAGO — Adults with elevated liproprotein(a) at high risk for a CV event saw substantial reductions over 12 weeks with muvalaplin, an investigational oral small molecule Lp(a) inhibitor, data from a phase 2 study show.

A single combined measure of three modifiable biomarkers in healthy women at midlife was predictive of 30-year risk for future cardiovascular events, according to new research presented at the European Society of Cardiology Congress.

An estimated 16 million U.S. adults who qualified for statin and/or antihypertensive therapy would not be eligible for primary prevention under the American Heart Association’s new PREVENT risk calculator, researchers reported in JAMA.

Elevated lipoprotein(a), despite a coronary artery calcium score of 0, could portend coronary plaque burden and may be a potential marker for early atherosclerosis intervention, researchers reported.